Prospective Randomized Control Pilot Study to Compare the Role of Injection Cerebrolysin in Operated cases of Degenerative Cervical Myelopathy.
Journal
Spine
ISSN: 1528-1159
Titre abrégé: Spine (Phila Pa 1976)
Pays: United States
ID NLM: 7610646
Informations de publication
Date de publication:
15 Jan 2022
15 Jan 2022
Historique:
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Prospective randomized control trial. The aim of this study was to analyze role of cerebrolysin in patients of degenerative cervical myelopathy (DCM) managed by surgical modalities. Cerebrolysin has been extensively researched with variable success in neurodegenerative pathologies. There has been only one study in published literature till date that has studied role of cerebrolysin in DCM in conservatively managed patients but none in the patients treated surgically. We present our pilot study which analyzes the role of cerebrolysin in patients of DCM managed by surgical modalities. This prospective randomized control trial was conducted at a tertiary care institute in Mumbai. Sixty operated cases of DCM were randomly divided into 2 groups. The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively. The second group was given placebo. Modified Japanese Orthopedic Association scores (mJOA) and visual analog scale (VAS) were used to document functional outcomes at 3 weeks, 3 months, 6 months, and 1 year. Recovery of hand function was separately accessed by improvement in hand power and sensations. Preoperative mJOA and VAS scores were comparable between 2 groups. Both groups showed significant improvement in both mJOA and VAS scores at 3weeks, 3 months, 6 months and 1-year follow-up (P < 0.01). In comparing the two groups, there was no difference in improvement of mJOA and VAS scores. However, cerebrolysin group showed significant improvement in hand function at 1 year compared to the placebo. Postoperative neurological recovery was better in the cerebrolysin group with 66.7% patients showing complete neurological recovery compared to 56.7% for placebo, but this was statistically insignificant. Two patients developed headache and one patient complained of dizziness in the cerebrolysin group, but these resolved without any intervention. Use of cerebrolysin in postoperative cases of DCM is safe and results in improved hand function.Level of Evidence: 1.
Sections du résumé
STUDY DESIGN
METHODS
Prospective randomized control trial.
OBJECTIVE
OBJECTIVE
The aim of this study was to analyze role of cerebrolysin in patients of degenerative cervical myelopathy (DCM) managed by surgical modalities.
SUMMARY OF BACKGROUND DATA
BACKGROUND
Cerebrolysin has been extensively researched with variable success in neurodegenerative pathologies. There has been only one study in published literature till date that has studied role of cerebrolysin in DCM in conservatively managed patients but none in the patients treated surgically. We present our pilot study which analyzes the role of cerebrolysin in patients of DCM managed by surgical modalities.
METHODS
METHODS
This prospective randomized control trial was conducted at a tertiary care institute in Mumbai. Sixty operated cases of DCM were randomly divided into 2 groups. The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively. The second group was given placebo. Modified Japanese Orthopedic Association scores (mJOA) and visual analog scale (VAS) were used to document functional outcomes at 3 weeks, 3 months, 6 months, and 1 year. Recovery of hand function was separately accessed by improvement in hand power and sensations.
RESULTS
RESULTS
Preoperative mJOA and VAS scores were comparable between 2 groups. Both groups showed significant improvement in both mJOA and VAS scores at 3weeks, 3 months, 6 months and 1-year follow-up (P < 0.01). In comparing the two groups, there was no difference in improvement of mJOA and VAS scores. However, cerebrolysin group showed significant improvement in hand function at 1 year compared to the placebo. Postoperative neurological recovery was better in the cerebrolysin group with 66.7% patients showing complete neurological recovery compared to 56.7% for placebo, but this was statistically insignificant. Two patients developed headache and one patient complained of dizziness in the cerebrolysin group, but these resolved without any intervention.
CONCLUSION
CONCLUSIONS
Use of cerebrolysin in postoperative cases of DCM is safe and results in improved hand function.Level of Evidence: 1.
Identifiants
pubmed: 34889883
doi: 10.1097/BRS.0000000000004131
pii: 00007632-202201150-00007
doi:
Substances chimiques
Amino Acids
0
cerebrolysin
37KZM6S21G
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
E58-E63Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ghogawala Z, Benzel EC, Riew KD, et al. Surgery vs conservative care for cervical spondylotic myelopathy: surgery is appropriate for progressive myelopathy. Neurosurgery 2015; 62: (suppl 1): 56–61.
Tetreault L, Goldstein CL, Arnold P, et al. Degenerative cervical myelopathy: a spectrum of related disorders affecting the aging spine. Neurosurgery 2015; 77: (suppl 1): S51–67.
Sangondimath G, Mallepally AR, Marathe N, et al. Degenerative cervical myelopathy: recent updates and future directions. J Clin Orthop Trauma 2020; 11:822–829.
Wilson JR, Tetreault LA, Kim J, et al. State of the art in degenerative cervical myelopathy: an update on current clinical evidence. Neurosurgery 2017; 80: (3 suppl): S33–45.
Sharma A, Kishore H, Singh V, et al. Comparative study of functional outcome of anterior cervical decompression and interbody fusion with tricortical stand-alone iliac crest autograft versus stand-alone polyetheretherketone cage in cervical spondylotic myelopathy. Global spine journal 2018; 8:860–865.
Bhosale S, Ingale P, Srivastava S, et al. Diffusion tensor imaging as an additional postoperative prognostic predictor factor in cervical myelopathy patients: an observational study. J Craniovertebr Junction Spine 2019; 10:10–13.
Alvarez XA, Sampedro C, Perez P. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with post-acute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol 2003; 18:271–278.
Wong GK, Zhu HL, Poon WS. Beneficial effects of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochir 2005; 95: (suppl): 59–60.
Panisset M, Gauthier S, Moessler H, et al. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 2002; 109:1089–1104.
Guekht AB, Moessler H, Novak PH, et al. on behalf of the Cerebrolysin Investigators. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis 2011; 20:310–318.
Allam AFA, Abotakia TAA, Koptan W. Role of cerebrolysin in cervical spondylotic myelopathy patients: a prospective randomized study. Spine J 2018; 18:1136–1142.
Shimomura T, Sumi M, Nishida K, et al. Prognostic factors for deterioration of patients with cervical spondylotic myelopathy after nonsurgical treatment. Spine (Phila Pa 1976) 2007; 32:2474–2479.
Tetreault L, Goldstein CL, Arnold P, et al. Degenerative cervical myelopathy: a spectrum of related disorders affecting the aging spine. Neurosurgery 2015; 77: (suppl 4): S51–67.
Karadimas SK, Erwin WM, Ely CG, et al. Pathophysiology and natural history of cervical spondylotic myelopathy. Spine (Phila Pa 1976) 2013; 38:S21–36.
Fehlings MG, Skaf G. A review of the pathophysiology of cervical spondylotic myelopathy with insights for potential novel mechanisms drawn from traumatic spinal cord injury. Spine (Phila Pa 1976) 1998; 23:2730–2736.
Mattei TA, Goulart CR, Milano JB, et al. Cervical spondylotic myelopathy: pathophysiology, diagnosis, and surgical techniques. ISRN Neurol 2011; 2011:463729.
Lestini WF, Wiesel SW. The pathogenesis of cervical spondylosis. Clin Orthop Relat Res 1989; 239:69–93.
Baptiste DC, Fehlings MG. Pathophysiology of cervical myelopathy. Spine J 2006; 6:190S–7.
Human and animal model evidence supporting a role for Cx3cr1 in mediating the inflammatory response in cervical spondylotic myelopathy. Abstract Presented at: The 2012 Society for Neuroscience meeting in October; New Orleans; 2012.
Karadimas SK, Moon E, Fehlings M. The sodium channel/glutamate blocker riluzole is complementary to decompression in a preclinical experimental model of cervical spondylotic myelopathy: implications for translational clinical application. Neurosurgery 2012; 71:E543.
Karadimas SK, Laliberte AM, Tetreault L, et al. Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. Sci Transl Med 2015; 7:316ra194.
Ning ZC, Li B. The determining of the amino acid contents and the peptide mapping of injection of cerebroprotein hydrolysate. Heilongjiang Yiyao 2002; 15:430–432.
Menon PK, Muresanu DF, Sharma A, et al. Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS Neurol Disord Drug Targets 2012; 11:40–49.
Schauer E, Wronski R, Patockova J. Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post-lesion application indicates a wide therapeutic window. J Neural Transm 2006; 113:855–868.
Patockova J, Krsiak M, Marhol P, et al. Cerebrolysin inhibits lipid peroxidation induced by insulin hypoglycemia in the brain and heart of mice. Physiol Res 2003; 52:455–460.
Chang WH, Park C, Kim DY, et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurol 2016; 16:31.
St MI, Poeata I, Ungureanu D, et al. Traumatic spinal cord injuries: neuroprotection and recent outcomes. Romanian Neurosurgery 2012; 210–216.
Aggarwal RA, Srivastava SK, Bhosale SK, et al. Prediction of surgical outcome in compressive cervical myelopathy: a novel clinicoradiological prognostic score. J Craniovertebr Junction Spine 2016; 7:82–86.
Rathod T, Garje V, Marathe N, et al. Incidence and outcome analysis of vertebral artery injury in posttraumatic cervical spine. Asian J Neurosurg 2020; 15:644–647.